{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:11:28Z","timestamp":1784308288899,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","award":["2023-10-012"],"award-info":[{"award-number":["2023-10-012"]}],"id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vaccine.2025.127648","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:41:07Z","timestamp":1756338067000},"page":"127648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea"],"prefix":"10.1016","volume":"63","author":[{"given":"Chelim","family":"Cheong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Suk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kyung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127648_bb0005","series-title":"Open forum infectious diseases","article-title":"Burden of herpes zoster in individuals with chronic conditions in the Republic of Korea: A Nationwide population-based database study","author":"Chen","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127648_bb0010","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s15010-023-02156-y","article-title":"Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns","volume":"52","author":"Steinmann","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2025.127648_bb0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcv.2010.01.003","article-title":"Disease burden of herpes zoster in Korea","volume":"47","author":"Choi","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2025.127648_bb0020","series-title":"Therapeutic advances in vaccines and immunotherapy","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127648_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2013.11.018","article-title":"Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical\u2013epidemiological study","volume":"20","author":"Song","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127648_bb0030","article-title":"Vaccines for preventing herpes zoster in older adults","author":"de Oliveira","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2025.127648_bb0035","first-page":"363","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis","author":"Tricco","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.127648_bb0040","first-page":"279","article-title":"ACIP releases 2018 adult immunization recommendations","volume":"97","author":"Savoy","year":"2018","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2025.127648_bb0045","series-title":"MMWR morbidity and mortality weekly Report","first-page":"71","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged\u2265 19 years: recommendations of the advisory committee on immunization practices\u2014United States, 2022","author":"Anderson","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127648_bb0050","doi-asserted-by":"crossref","first-page":"2168952","DOI":"10.1080\/21645515.2023.2168952","article-title":"Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: an updated critical review","volume":"19","author":"Giannelos","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127648_bb0055","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.amepre.2023.05.007","article-title":"Cost-effectiveness of recombinant zoster vaccine for adults aged\u2265 50 years in China","volume":"65","author":"Jiang","year":"2023","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2025.127648_bb0060","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s13555-022-00744-8","article-title":"Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults","volume":"12","author":"Teng","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.vaccine.2025.127648_bb0065","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.vaccine.2024.05.016","article-title":"The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: a mathematical modelling study","volume":"42","author":"Kim","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127648_bb0070","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/vaccines12080886","article-title":"Prioritization of vaccines for introduction in the National Immunization Program in the Republic of Korea","volume":"12","author":"Choi","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127648_bb0075","article-title":"Recurrence rate of herpes zoster and its risk factors: a population-based cohort study","volume":"34","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2025.127648_bb0080","unstructured":"Statistics Korea. Population Trend Survey, https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1B80A13&conn_path=I2 [accessed 2025.03.18]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3346\/jkms.2016.31.1.13","article-title":"Immunogenicity and safety of a live attenuated zoster vaccine (ZOSTAVAX\u2122) in Korean adults","volume":"31","author":"Choi","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2025.127648_bb0090","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2025.127648_bb0095","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127648_bb0100","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127648_bb0105","first-page":"381","article-title":"Herpes zoster vaccines: WHO position paper. The","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2025.127648_bb0110","series-title":"Open forum infectious diseases","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","author":"Strezova","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127648_bb0115","unstructured":"National Health Insurance Corporation. 2021 Health Insurance Patient Treatment Cost Status Survey, https:\/\/stat.kosis.kr\/nsibsHtmlSvc\/fileView\/FileStbl\/fileStblView.do?in_org_id=350&in_tbl_id=DT_350005_FILE2021&tab_yn=N&conn_path=E1; [accessed 2025.02.07]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0120","unstructured":"Korean Statistical Information Service. 2021 Employment rate and hourly wage in Korea, https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1DA7002S&conn_path=I2, https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=118&tblId=DT_118N_LCE0001&conn_path=I2; [accessed 2025.03.12]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","article-title":"Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice","volume":"153","author":"Bouhassira","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.vaccine.2025.127648_bb0130","unstructured":"Regional GDP. Gross regional income and Households and NPISHs income per Capita, https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1C96&conn_path=I2&language=en; 2023 [accessed 2025.02.14]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0135","unstructured":"Health Insurance Review & Assessment Service. Information on the cost-effectiveness evaluation results (ICER) of drugs submitted for economic evaluation in 2019\u20132023, https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=11273&pageIndex=1&pageIndex2=1#none; [accessed June.08]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0140","article-title":"Cost-effectiveness of herpes zoster vaccines in the US: a systematic review","volume":"29","author":"Meredith","year":"2022","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.vaccine.2025.127648_bb0145","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/vaccines12080872","article-title":"Cost-effectiveness analysis of herpes zoster vaccination in a Chinese population: recombinant subunit vaccine versus live attenuated vaccine","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127648_bb0150","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.vaccine.2019.05.006","article-title":"Cost-effectiveness of recombinant zoster vaccine (RZV) and varicella vaccine live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan","volume":"37","author":"Hoshi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127648_bb0155","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciy1099","article-title":"Systematic review and meta-analysis of chickenpox vaccination and risk of herpes zoster: a quantitative view on the \u201cexogenous boosting hypothesis\u201d","volume":"69","author":"Harder","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127648_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.127648_bb0165","series-title":"WHO guide for standardization of economic evaluations of immunization programmes","author":"Organization WH","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127648_bb0170","first-page":"83","article-title":"What should the cost-effectiveness threshold reflect?","author":"Bae","year":"2018","journal-title":"Korean J Health Econ Policy"},{"key":"10.1016\/j.vaccine.2025.127648_bb0175","author":"The Korean Society of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2025.127648_bb0180","author":"Ministry of the Interior and Safety in the Republic of Korea"},{"key":"10.1016\/j.vaccine.2025.127648_bb0185","author":"Statistics Korea"},{"key":"10.1016\/j.vaccine.2025.127648_bb0190","series-title":"Pensions at a glance 2023","author":"OECD","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127648_bb0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.socscimed.2017.02.013","article-title":"Disability, poverty, and role of the basic livelihood security system on health services utilization among the elderly in South Korea","volume":"178","author":"Jeon","year":"2017","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2025.127648_bb0200","unstructured":"United States Medicare official website. Shingles shots, https:\/\/www.medicare.gov\/coverage\/shingles-shots; [accessed 2024.01.24]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0205","unstructured":"Government of Canada. Herpes zoster (shingles) vaccine: Canadian Immunization Guide, https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html; 2024 [accessed 2024.08.24]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0210","author":"Ministry of Health"},{"key":"10.1016\/j.vaccine.2025.127648_bb0215","unstructured":"Prince Edward Island. Prince Edward Island Recommended Adult Vaccines 2024."},{"key":"10.1016\/j.vaccine.2025.127648_bb0220","author":"Gouvernement du Qu\u00e9bec"},{"key":"10.1016\/j.vaccine.2025.127648_bb0225","unstructured":"Government of Yukon Health and Social Services. Immunization schedules, https:\/\/yukonimmunization.ca\/get-immunized\/immunization-schedules; [accessed 2024.08.28]."},{"key":"10.1016\/j.vaccine.2025.127648_bb0230","author":"Australian Government Department of Health and Aged Care"},{"key":"10.1016\/j.vaccine.2025.127648_bb0235","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.vaccine.2021.03.056","article-title":"The impact of two-dose varicella vaccination on varicella and herpes zoster incidence in South Korea using a mathematical model with changing population demographics","volume":"39","author":"Suh","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127648_bb0240","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jmv.23830","article-title":"Immunity and the burden of herpes zoster","volume":"86","author":"Choi","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2025.127648_bib241","author":"UK Health Security Agency"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T03:52:03Z","timestamp":1765857123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"alternative-id":["S0264410X25009454"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127648","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127648"}}